OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Other Events
Item 8.01 Other Events.
that it had sold an aggregate of approximately 3.6 million shares
of its common stock under its previously announced “at the
market offering” program during the fourth quarter of 2016,
resulting in aggregate net proceeds to the Company of
approximately $4.6 million.
entered into a Sales Agreement with Cowen and Company, LLC
(“Cowen”) to which the Company may offer and sell from time to
time in an “at the market offering”, at its option, up to an
aggregate of $25 million of shares of its common stock through
Cowen, as sales agent, with initial sales to be limited to an
aggregate of $11.5 million of shares of the Company’s common
stock.
market offering” are made to a prospectus supplement to the
Company’s previously filed and currently effective shelf
Registration Statement on Form S-3 (File No. 333-213356). This
Current Report on Form 8-K shall not constitute an offer to sell
or the solicitation of an offer to buy the securities discussed
herein, nor shall there be any offer, solicitation, or sale of
the securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
| (d) |
Exhibits.
|
| 99.1 |
Press Release, dated December 16, 2016, issued by OpGen,
Inc. |
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name. OpGen, Inc. (NASDAQ:OPGN) Recent Trading Information
OpGen, Inc. (NASDAQ:OPGN) closed its last trading session down -0.08 at 1.06 with 1,622,078 shares trading hands.